Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study
PLOS One · 22.05.2026 · 21 (5) · e0350024
DOI: 10.1371/journal.pone.0350024 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS One, online erschienen am 22.05.2026. Verfasst von Wenxin Jiang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Scie…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Ki-67 Antigen, Lymphoma, Large B-Cell, Diffuse. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Lymphoma Research Fund of China Anti-Cancer Association.
Abstract (Originalsprache)
Objectives
To compare the safety and efficacy of first-line dose-adjusted EPOCH-R (DA-EPOCH-R) versus R-CHOP treatment in diffuse large B-cell lymphoma (DLBCL) patients with high Ki67 expression.
Methods
A retrospective analysis of DLBCL patients receiving R-CHOP determined the threshold of high Ki67 expression predicting 2-year progression-free survival (PFS) events using receiver operating characteristic (ROC) curve. Then we initiated a prospective, observational study evaluating DA-EPOCH-R therapy for DLBCL with high Ki67 expression, and selected a retrospective R-CHOP cohort to perform a propensity score-matched (PSM) analysis. Primary endpoints were PFS and overall survival (OS).
Results
A Ki67 threshold of 82.5% was determined using ROC in the retrospective analysis of 376 DLBCL cases, thus the threshold was ultimately set at 80%. A total of 29 patients receiving DA-EPOCH-R were enrolled in the prospective study, the enrollment was terminated due to the conditional power and a slow accrual. Following 1:1 PSM, no PFS (HR 0.93, 95% CI: 0.47–1.84, p = 0.83) and OS (HR 1.28, 95% CI: 0.42–3.83, p = 0.66) benefit of DA-EPOCH-R versus R-CHOP was observed, with a nearly significantly higher frequency of grade ≥ 3 hematological adverse events (AEs) observed in the DA-EPOCH-R group (p = 0.052). Notably, only 37.9% (11/29) of patients executed dose escalation, which indicated a worse tolerance to this intensified regimen of the East Asians.
Conclusions
No significant survival benefit from DA-EPOCH-R treatment was observed for DLBCL with high Ki67 expression, which may be attributed to the poorer tolerance in the East Asian population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
ORCID-Profile: Peng Liu
Förderung
- The Lymphoma Research Fund of China Anti-Cancer Association
Zitieren
APA
Jiang, W., & Liu, P. (2026). Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study. PLOS One, 21(5), e0350024. https://doi.org/10.1371/journal.pone.0350024
Vancouver
Jiang W, Liu P. Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study. PLOS One. 2026;21(5):e0350024. doi:10.1371/journal.pone.0350024
BibTeX
@article{Jiang2026,
author = {Jiang, Wenxin and Liu, Peng},
title = {Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {5},
pages = {e0350024},
doi = {10.1371/journal.pone.0350024}
}
EUVIMED